The JAK2 V617F mutation occurs frequently in myelodysplastic/ myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis [12]

Leukemia

Volumn 20, Issue 7, 2006, Pages 1315-1316

  Kremer, M ^a   Horn, T ^a   Dechow, T ^a   Tzankov, A ^b   Quintanilla Martinez L ^c   Fend, F ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; JANUS KINASE 2; PHENYLALANINE; VALINE;

BONE MARROW BIOPSY; CHROMOSOME DELETION; CHROMOSOME DELETION 12; CHROMOSOME DELETION 13; CHROMOSOME DELETION 20; CHROMOSOME DELETION 5; CHROMOSOME TRANSLOCATION 10; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 2; CHROMOSOME TRANSLOCATION 21; CLINICAL FEATURE; CONTROLLED STUDY; FIBROSIS; GENE FUSION; GENE MUTATION; HUMAN; HUMAN TISSUE; LETTER; MAJOR CLINICAL STUDY; MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISEASE; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 33745199895     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404231     Document Type: Letter

References (9)

1. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
2. James C, Ugo V, Casadevall N, Constantinescu S, Vainchenker W. A JAK2 mutation in myeloproliferative disorders: Pathogenesis and therapeutic and scientific prospects. Trends Mol Med 2005; 11: 546-554.
3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
4. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
5. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferative disorders and myelodysplastic syndromes. Blood 2005; 106: 1207-1209.
6. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S et al. JAK2 mutation 1849G >T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukemia. Blood 2005; 106: 3370-3373.
7. Ohyashiki K, Aota Y, Akahane D, Gotoh A, Miyazawa K, Kimura Y et al. The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia 2005; 19: 2359-2360.
8. Levine RL, Loriaux M, Huntly BJ, Loh M, Beran M, Stoffregen E et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106: 3377-3379.
9. Johan M, Goodeve A, Bowen D, Frew M, Reilly J. JAK2 V617F Mutation is uncommon in chronic myelomonocytic leukemia. Br J Haematol 2005; 130: 968.